Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.37
-9.9%
$2.93
$2.35
$4.60
$20.93M1.236,292 shs101,472 shs
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
$1.80
+2.4%
$1.43
$0.19
$2.65
$31.73M3.081.39 million shs41,410 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%-15.96%-17.71%-17.71%-54.21%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
+2.41%+34.51%+26.05%+27.84%-44.37%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.4926 of 5 stars
3.35.00.00.03.30.00.0
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.50
Moderate Buy$12.00406.33% Upside
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
0.00
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INNVD, HILS, PXSLY, and DARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$10K2,097.45N/AN/A($0.69) per share-3.43
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/A$0.48 per shareN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$0.17N/AN/AN/A-191.65%N/A-8.14%8/11/2025 (Estimated)
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A

Latest INNVD, HILS, PXSLY, and DARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
3/31/2025Q4 2024
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.56
0.56
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/A
3.01
3.01
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92

Institutional Ownership

CompanyInstitutional Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
13.36%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A

Insider Ownership

CompanyInsider Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.00%
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
30.24%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
308.85 million8.50 millionNot Optionable
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
117.60 million12.28 millionNot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.37 -0.26 (-9.89%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.01 (+0.63%)
As of 06/27/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Hillstream BioPharma stock logo

Hillstream BioPharma NASDAQ:HILS

$1.80 +0.04 (+2.41%)
As of 06/27/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.